According to the company's regulatory filing, the inspection was conducted from July 20 to July 29, 2026. At the conclusion of the inspection, the USFDA issued a Form 483 containing three observations. Dr. Reddy's stated that it will respond to the observations within the stipulated timeline in accordance with regulatory requirements. A Form 483 is issued by the USFDA when investigators identify conditions that may require corrective action. Also Read: Recalls by Dr Reddy's, Torrent Put Spotlight on Quality Standards in India's Semaglutide Market